Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

134P - Clinical and epidemiological patterns of pleural mesothelioma in the United States: Long-term data from SEER database


31 Mar 2023


Poster Display session


Mohamed Ahmed


Journal of Thoracic Oncology (2023) 18 (4S): S116-S118.


M. Ahmed1, L.N. Sherif2, A.A. Bahbah3, A.H. Allam3, M.T. Khallafallah4, O.A. Aboshady5

Author affiliations

  • 1 Benha/EG
  • 2 Menoufia University, Faculty of Medicine, Shebin El-Kom/EG
  • 3 Faculty of Medicine, Menoufia University, Shebin El-Kom/EG
  • 4 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Shebin El-Kom/EG
  • 5 Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom/EG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 134P


Malignant pleural mesothelioma is a rare and aggressive cancer type with a rising global incidence over the past decade. In this study, we aimed to assess the clinical and epidemiological patterns of pleural mesothelioma in the United States. Moreover, we tracked the changing trend of overall survival and disease distribution of the different histological subtypes.


We used Surveillance, Epidemiology, and End Results Program (SEER) database to extract data of cases diagnosed with microscopically confirmed malignant pleural mesothelioma between 2004 and 2019 [17 reg; Nov 2021 sub]. Cases with unknown/unreported stage were excluded.


We analyzed data from 9,511 malignant pleural mesothelioma patients. Most cases were males (77.6%, n = 7384), of white race (90.8%, n = 8635), ≥70 years at diagnosis (65.3%, n = 6215), and presented with distant disease (70.5%, n = 6703). The overall incidence rate of pleural mesothelioma was 7.2 per million and decreased from 7.7 per million in 2004 to 6.1 per million in 2019 with a marginal increase in the median overall survival (Table). Moreover, patients became more likely to present with localized and regional stages. Longitudinal tracking of cases with different histological subtypes showed an increase in the epithelioid mesothelioma which had a statistically significant longer median overall survival compared with fibrous mesothelioma and biphasic mesothelioma (12 months vs. 4 and 8 months, respectively; P = 0.001).

Table: 134P

Distribution and overall survival of pleural mesothelioma cases between 2004 and 2019

9050/3 Mesothelioma (NOS)54.2%52.6%52%48.7%46.2%46.9%41.5%38.4%37.6%39.239%34.8%32.7%27%31.1%37.3%
9051/3 Fibrous mesothelioma10%11%11.7%10.9%12.3%10.8%13.7%13.5%14.3%11.3%10%11.2%9.6%11.7%11%12.4%
9052/3 Epithelioid mesothelioma28.8%30.7%32.6%31.8%35.9%35.3%36.8%38.8%38.6%41.4%40.2%44.2%48.2%50.2%45.1%42.7%
9053/3 Biphasic mesothelioma7%5.8%3.8%8.7%5.5%7%8%9.3%9.6%8.1%10.7%9.8%9.6%11%12.8%7.7%
Overall survival (months)778788898899101010Not reached


The incidence of pleural mesothelioma decreased between 2004 and 2019 with a marginal improvement in the median overall survival. However, there is a substantial increase in the proportion of patients presenting with epithelioid mesothelioma and those presenting with localized stage.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.